| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
(24S)-24,25-Dihydroxyvitamin D3 targets the vitamin D receptor (VDR) and related signaling pathways. As an inactive form of vitamin D3, it has lower affinity for VDR compared to the active form 1,25-dihydroxyvitamin D3. It has some bone calcium mobilizing activity and stimulates intestinal calcium transport. The compound is produced in the liver and plays a role in regulating calcium and phosphate metabolism.
|
|---|---|
| ln Vitro |
(24S)-24,25-Dihydroxyvitamin D3 ((24S)-24,25-dihydroxycholecalciferol) is a 24,25-dihydroxyvitamin D3 isomer. In the kidneys, vitamin D is metabolized to 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3, whereas in the liver, it is converted to 25-hydroxyvitamin D3 [5].
In vitro, (24S)-24,25-Dihydroxyvitamin D3 has some bone calcium mobilizing activity and stimulates intestinal calcium transport. As an inactive form of vitamin D3, its activity is lower than that of the active metabolite 1,25-dihydroxyvitamin D3. Its biological activity has been characterized in cell-based assays measuring VDR activation and calcium transport. |
| ln Vivo |
In vivo, (24S)-24,25-Dihydroxyvitamin D3 is produced in the liver from 25-hydroxyvitamin D3 and plays a role in regulating calcium and phosphate metabolism. It is an inactive form of vitamin D3 that can be further hydroxylated to form active vitamin D3 analogs. The compound has some bone calcium mobilizing activity and stimulates intestinal calcium transport.
|
| Enzyme Assay |
The in vitro receptor binding assay for (24S)-24,25-Dihydroxyvitamin D3 involves measuring its affinity for the vitamin D receptor (VDR). Purified VDR or cell lysates from VDR-expressing cells are incubated with radiolabeled 1,25-dihydroxyvitamin D3 (e.g., 3H-1,25(OH)2D3) and varying concentrations of (24S)-24,25-Dihydroxyvitamin D3 (typically 0.001 nM to 10 uM) in binding buffer at 4degC for 2-4 hours. Bound and free ligand are separated by charcoal adsorption or hydroxyapatite chromatography, and radioactivity is measured by scintillation counting. The relative binding affinity is calculated from competition curves.
|
| Cell Assay |
In vitro cellular assays for (24S)-24,25-Dihydroxyvitamin D3 are conducted using VDR-expressing cell lines such as osteoblasts, intestinal epithelial cells, or kidney cells. Cells are seeded in multi-well plates and treated with varying concentrations of the compound (typically 0.01 nM to 10 uM) for 24-48 hours. VDR activation is assessed by measuring the expression of VDR target genes (e.g., CYP24A1, osteocalcin) by qPCR. Calcium transport is measured in intestinal epithelial cell models using radioactive ⁴⁵Ca or fluorescent calcium indicators. Cell viability is monitored using MTT or similar assays.
|
| Animal Protocol |
In vivo animal studies for (24S)-24,25-Dihydroxyvitamin D3 typically involve administration to rodents to assess its effects on calcium and phosphate metabolism. The compound is administered by oral gavage or intraperitoneal injection at doses ranging from 0.01-10 ug/kg/day for 1-4 weeks. Serum calcium, phosphate, and vitamin D metabolite levels are measured. Bone mineral density is assessed by DEXA or micro-CT. Intestinal calcium transport is measured using everted gut sac assays or by assessing calcium absorption using radioactive tracers. At study termination, tissues are harvested for histological examination and gene expression analysis.
|
| ADME/Pharmacokinetics |
(24S)-24,25-Dihydroxyvitamin D3 has a molecular weight of 416.64 and a molecular formula of C27H44O3. It is insoluble in water (8.3E-4 g/L at 25degC). As a lipophilic compound, it is typically formulated in oil-based or organic solvent-based vehicles for in vivo administration. The compound is a metabolite of vitamin D3 that is produced in the liver and undergoes further hydroxylation to form active vitamin D analogs.
|
| Toxicity/Toxicokinetics |
The toxicological profile of (24S)-24,25-Dihydroxyvitamin D3 is characteristic of vitamin D metabolites. At high doses, vitamin D compounds can cause hypercalcemia and soft tissue calcification. The compound is for research use only and is not intended for human therapeutic use. Standard safety precautions should be followed when handling the compound. No specific LD50 values have been reported.
|
| References |
|
| Additional Infomation |
(24S)-24,25-Dihydroxyvitamin D3 (CAS 55700-58-8) is a metabolite of vitamin D3, also known as 24,25(OH)2D3. It is an inactive form of vitamin D3 that undergoes hydroxylation to form active vitamin D analogs. The compound has some bone calcium mobilizing activity and stimulates intestinal calcium transport. It is available for research purposes only.
|
| Molecular Formula |
C27H44O3
|
|---|---|
| Molecular Weight |
416.63646
|
| Exact Mass |
416.329
|
| CAS # |
55700-58-8
|
| PubChem CID |
5283749
|
| Appearance |
White to off-white solid powder
|
| Density |
1.06g/cm3
|
| Boiling Point |
571.1ºC at 760mmHg
|
| Flash Point |
241.5ºC
|
| Index of Refraction |
1.547
|
| LogP |
5.704
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
30
|
| Complexity |
688
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C[C@H](CC[C@@H](C(C)(C)O)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C
|
| InChi Key |
FCKJYANJHNLEEP-WQUHCOROSA-N
|
| InChi Code |
InChI=1S/C27H44O3/c1-18-8-12-22(28)17-21(18)11-10-20-7-6-16-27(5)23(13-14-24(20)27)19(2)9-15-25(29)26(3,4)30/h10-11,19,22-25,28-30H,1,6-9,12-17H2,2-5H3/b20-10+,21-11-/t19-,22+,23-,24+,25+,27-/m1/s1
|
| Chemical Name |
(3S,6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-2,3-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~240.02 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (6.00 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.00 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4002 mL | 12.0008 mL | 24.0015 mL | |
| 5 mM | 0.4800 mL | 2.4002 mL | 4.8003 mL | |
| 10 mM | 0.2400 mL | 1.2001 mL | 2.4002 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
